Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
120 hedge funds and large institutions have $1.05B invested in Revance Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 26 reducing their positions, and 16 closing their positions.
132% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $1.35M
100% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 26
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
4% more funds holding
Funds holding: 115 → 120 (+5)
16% less capital invested
Capital invested by funds: $1.25B → $1.05B (-$196M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$20.1M |
| 2 |
Millennium Management
New York
|
+$12.7M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$10.3M |
| 4 |
BlackRock
New York
|
+$7.79M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
NovaQuest Capital Management
Raleigh,
North Carolina
|
-$49.5M |
| 2 |
DM
Deerfield Management
New York
|
-$35.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.7M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$8.45M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$7.11M |
RVNC Hedge Fund Activity: Q1 2018 in Review
120 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2018, worth a combined $1.05B — down 16% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RVNC positions and 16 closed out — a net gain of 5 holders — while 52 added to existing stakes and 26 trimmed.
The largest buyer was Jennison Associates, adding an estimated $20.1M. The largest seller was NovaQuest Capital Management, cutting an estimated $49.5M.
- 120 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2018, up from 115 in Q4 2017.
- Funds reported $1.05B of Revance Therapeutics, Inc. stock for Q1 2018, down 16% quarter-over-quarter.
- 21 funds opened new Revance Therapeutics, Inc. positions in Q1 2018 and 16 closed out, a net change of +5 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2018 was Jennison Associates, an estimated $20.1M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2018 was NovaQuest Capital Management, an estimated $49.5M sold.
Based on aggregated 13F filings for Q1 2018.